drugset / Trial / NCT06790290
Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants
Phase 2
Active not recruiting
421 enrolled
Inventprise Inc.
Grand Centennial Homes Clinic · collabHealth Index Multispecialty Clinic · collabUniversity of the Philippines-National Health Institute_Doña Nena Health Center · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Phase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants
Timeline
- Start
- 2025-01-27
- Primary completion
- 2025-04-03
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Formulation B | Vaccine | 0.5 ml | Intramuscular |
| Comparator | PCV20 | Vaccine | 0.5 ml | Intramuscular |